https://www.prnewswire.co.uk/news-releases/bergenbio-enters-second-stage-of-phase-ii-trial-with-selective-axl-inhibitor-bemcentinib-in-combination-with-keytruda-in-patients-with-advanced-nsclc-855501672.html
BerGenBio Enters Second Stage of Phase II Trial With Selective AXL Inhibitor bemcentinib in...
/PRNewswire/ -- BerGenBio ASA (OSE: BGBIO) announces that the first patient has been dosed in the second stage of the phase II trial (BGBC008) evaluating the...
phase ii trialsecond stageaxl inhibitorentersselective